OBJECTIVES: The exact cause(s) of apparent overestimation of β cell mass (BCM) with vesicular monoamine transporter type 2 (VMAT2) PET imaging in type 1 diabetes (T1D) is unknown. The objectives were to estimate in baboons non-displaceable binding of [¹⁸F]fluoropropyl (FP)-(+)-dihydrotetrabenazine (DTBZ) with its inactive enantiomer, [¹⁸F]FP-(-)-DTBZ, to validate the use of the reference tissue (renal cortex or spleen) in VMAT2 quantification; and also to compare specific pancreatic VMAT2 binding with that of the striatum in the same baboon brains because high specific binding signal for the pancreas would be desirable for its accurate quantification. METHODS: Baboons (Papio ursinus) had multiple dynamic abdominal and brain PET scans each for 2 h with (+) and (-) enantiomers on separate occasions. Data were analyzed by compartmental models to estimate non-displaceable (V(ND)) and specific (V(S)) VMAT2 binding in respective organs. RESULTS: [¹⁸F]FP-DTBZ PET showed excellent target tissue signal and specific VMAT2 binding in the pancreas (Vs =41±11 mL/cm³) at nearly 80% that of the striatum. Directly estimated non-displaceable binding in the pancreas (V(ND) =12±1 mL/cm³) was similar to that of the renal cortex, spleen or cerebellum. CONCLUSION: ¹⁸FFP-DTBZ PET shows excellent specific VMAT2 binding in both the pancreas and striatum in baboons. The renal cortex or spleen as the reference tissue in VMAT2 quantification appears supported. However further studies appear warranted to directly estimate pancreatic non-displaceable binding in humans including T1D patients and also to clarify the cause of the apparent overestimation of BCM in T1D.
OBJECTIVES: The exact cause(s) of apparent overestimation of β cell mass (BCM) with vesicular monoamine transporter type 2 (VMAT2) PET imaging in type 1 diabetes (T1D) is unknown. The objectives were to estimate in baboons non-displaceable binding of [¹⁸F]fluoropropyl (FP)-(+)-dihydrotetrabenazine (DTBZ) with its inactive enantiomer, [¹⁸F]FP-(-)-DTBZ, to validate the use of the reference tissue (renal cortex or spleen) in VMAT2 quantification; and also to compare specific pancreatic VMAT2 binding with that of the striatum in the same baboon brains because high specific binding signal for the pancreas would be desirable for its accurate quantification. METHODS:Baboons (Papio ursinus) had multiple dynamic abdominal and brain PET scans each for 2 h with (+) and (-) enantiomers on separate occasions. Data were analyzed by compartmental models to estimate non-displaceable (V(ND)) and specific (V(S)) VMAT2 binding in respective organs. RESULTS: [¹⁸F]FP-DTBZ PET showed excellent target tissue signal and specific VMAT2 binding in the pancreas (Vs =41±11 mL/cm³) at nearly 80% that of the striatum. Directly estimated non-displaceable binding in the pancreas (V(ND) =12±1 mL/cm³) was similar to that of the renal cortex, spleen or cerebellum. CONCLUSION: ¹⁸FFP-DTBZ PET shows excellent specific VMAT2 binding in both the pancreas and striatum in baboons. The renal cortex or spleen as the reference tissue in VMAT2 quantification appears supported. However further studies appear warranted to directly estimate pancreatic non-displaceable binding in humans including T1D patients and also to clarify the cause of the apparent overestimation of BCM in T1D.
Authors: Rajesh Goswami; Datta E Ponde; Mei-Ping Kung; Catherine Hou; Mike R Kilbourn; Hank F Kung Journal: Nucl Med Biol Date: 2006-08 Impact factor: 2.408
Authors: Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung Journal: Nucl Med Biol Date: 2007-04 Impact factor: 2.408
Authors: Tarun Singhal; Yu-Shin Ding; David Weinzimmer; Marc D Normandin; David Labaree; Jim Ropchan; Nabeel Nabulsi; Shu-fei Lin; Marc B Skaddan; Walter C Soeller; Yiyun Huang; Richard E Carson; Judith L Treadway; Gary W Cline Journal: Mol Imaging Biol Date: 2010-09-08 Impact factor: 3.488
Authors: Yoshifumi Saisho; Paul E Harris; Alexandra E Butler; Ryan Galasso; Tatyana Gurlo; Robert A Rizza; Peter C Butler Journal: J Mol Histol Date: 2008-09-13 Impact factor: 2.611
Authors: Robin Goland; Matthew Freeby; Ramin Parsey; Yoshifumi Saisho; Dileep Kumar; Norman Simpson; Joy Hirsch; Martin Prince; Antonella Maffei; J John Mann; Peter C Butler; Ronald Van Heertum; Rudolph L Leibel; Masanori Ichise; Paul E Harris Journal: J Nucl Med Date: 2009-02-17 Impact factor: 10.057
Authors: Maarten E Tushuizen; Mathijs C Bunck; Petra J Pouwels; Saskia Bontemps; Jan Hein T van Waesberghe; Roger K Schindhelm; Andrea Mari; Robert J Heine; Michaela Diamant Journal: Diabetes Care Date: 2007-07-31 Impact factor: 19.112
Authors: Mei-Ping Kung; Catherine Hou; Brian P Lieberman; Shunichi Oya; Datta E Ponde; Eric Blankemeyer; Daniel Skovronsky; Michael R Kilbourn; Hank F Kung Journal: J Nucl Med Date: 2008-06-13 Impact factor: 10.057
Authors: Mika Naganawa; Keunpoong Lim; Nabeel B Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Kevan C Herold; Yiyun Huang; Paul Harris; Masanori Ichise; Gary W Cline; Richard E Carson Journal: Mol Imaging Biol Date: 2018-10 Impact factor: 3.488
Authors: Mika Naganawa; Shu-Fei Lin; Keunpoong Lim; David Labaree; Jim Ropchan; Paul Harris; Yiyun Huang; Masanori Ichise; Richard E Carson; Gary W Cline Journal: Nucl Med Biol Date: 2016-09-02 Impact factor: 2.408
Authors: Matthew J Freeby; Patricia Kringas; Robin S Goland; Rudolph L Leibel; Antonella Maffei; Chaitan Divgi; Masanori Ichise; Paul E Harris Journal: Mol Imaging Biol Date: 2015-09-14 Impact factor: 3.488